Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells 196,229 Shares of Stock
A major shareholder of ADC Therapeutics (NYSE:ADCT), Redmile Group, Llc, recently sold a significant number of shares, including 196,229 shares on March 31st and additional large blocks on April 2nd, reducing its ownership by 1.25%. Despite these insider sales totaling millions of dollars, ADCT's stock remained relatively flat, and analysts maintain a "Moderate Buy" rating with an average target price of $7.67. ADC Therapeutics is a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates for treating hematological malignancies.
Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells $8,641,179.68 in Stock
Redmile Group, a major shareholder in ADC Therapeutics (NYSE:ADCT), sold over 2.6 million shares totaling $8.6 million on April 2nd, 2026, reducing its stake by 17.22%. Despite the insider selling, ADC Therapeutics maintains a "Moderate Buy" rating from analysts with an average target price of $7.67. The company, a clinical-stage biopharmaceutical firm focusing on antibody-drug conjugates, has seen mixed institutional trading and currently trades at $3.81 with a market cap of $483.39 million.
Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells 169,265 Shares of Stock
Redmile Group, a major shareholder in ADC Therapeutics (NYSE:ADCT), sold multiple blocks of ADCT stock between March 31 and April 2, totaling approximately 5.9 million shares for about $19.6 million. Despite these sales, Redmile Group still holds around 15.3 million shares. ADC Therapeutics currently trades near $3.81 and has a "Moderate Buy" consensus analyst rating with an average target of $7.67, though the company remains loss-making.
Redmile-managed funds trim ADC Therapeutics (ADCT) stake with 5.9M-share sale
Funds managed by Redmile Group sold a total of 5,880,415 shares of ADC Therapeutics (ADCT) common stock in open-market transactions between March 31 and April 2, 2026. The sales occurred at weighted average prices ranging from approximately $3.28 to $3.80 per share. Despite these significant sales, Redmile-managed entities still retain a substantial position in ADC Therapeutics, totaling over 22 million shares across direct and indirect holdings.
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics SA announced the grant of options to purchase 17,000 common shares to a new employee as a material inducement for their employment. This grant was approved by the Compensation Committee under the Company's Inducement Plan and vests over four years, subject to continued employment. The company issued this press release in compliance with NYSE's Listed Company Manual Rule 303A.08.
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance
ADC Therapeutics is projecting peak annual revenue for its drug ZYNLONTA to be between $600 million and $1 billion. This forecast is based on the advancing clinical trials LOTIS-5 and LOTIS-7, which are assessing ZYNLONTA's potential to establish itself as a frontline treatment option. The company is actively working to expand the drug's label into earlier lines of therapy.
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
This article analyzes whether Acumen Pharmaceuticals (ABOS) and ADC Therapeutics SA (ADCT) are outperforming their medical sector peers. Both companies are highlighted for their positive year-to-date returns compared to the sector's average loss. The analysis uses Zacks Rank and consensus EPS estimates to suggest their continued strong performance.
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
ADC Therapeutics (NYSE: ADCT) reported its fourth quarter and full year 2025 financial results, highlighting net product revenues of $22.3 million for Q4 and $73.6 million for the full year. The company expects topline data from its LOTIS-5 Phase 3 trial in Q2 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026, and maintains a cash runway at least into 2028. An amendment to its HealthCare Royalty financing agreement has also increased strategic flexibility.
ADC Therapeutics Eyes ZYNLONTA Expansion as LOTIS-5 Data Nears at H.C. Wainwright Chat
ADC Therapeutics is strategically focusing on expanding its CD19-directed antibody-drug conjugate ZYNLONTA into earlier lines of Diffuse Large B-cell Lymphoma (DLBCL) and indolent lymphomas, moving beyond its current third-line approval. Key to this expansion are the upcoming top-line data from the Phase III LOTIS-5 study, expected in Q2, which could significantly increase the addressable patient population and drive revenue growth. Additionally, promising early data from the Phase Ib LOTIS-7 study, combining ZYNLONTA with glofitamab, showed high response rates and reduced cytokine release syndrome, further supporting the drug's potential in combination therapies.
ADC Therapeutics (NYSE:ADCT) Shares Gap Up on Analyst Upgrade
ADC Therapeutics (NYSE:ADCT) shares gapped up after HC Wainwright raised its price target to $8 from $7, maintaining a "buy" rating. The stock opened at $4.10, up from a prior close of $3.86, and is trading around $4.00. The company recently reported an earnings beat, with EPS of -$0.04 against an expected -$0.32, and revenue of $23.06 million versus $22.29 million, although it remains loss-making.
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00
HC Wainwright has raised its price target for ADC Therapeutics (NYSE:ADCT) to $8.00 from $7.00, maintaining a "buy" rating and suggesting a significant upside. The company recently surpassed analysts' estimates for both earnings and revenue in its latest quarterly report. The consensus among analysts for ADCT is a "Moderate Buy" with an average target price of $7.67.
Heights Capital Management Inc. Has $1.31 Million Position in ADC Therapeutics SA $ADCT
Heights Capital Management Inc. significantly reduced its stake in ADC Therapeutics (NYSE:ADCT) by 88.5% in Q3, now holding 326,766 shares valued at approximately $1.31 million. Despite this, other hedge funds increased their positions, and the company reported strong Q3 earnings, beating EPS estimates by $0.28. Analysts maintain a "Moderate Buy" rating for ADCT with an average price target of $7.33, while the stock trades around $4.11.
[EFFECT] ADC Therapeutics SA SEC Filing
ADC Therapeutics SA (ADCT) had an EFFECT filing declared effective on March 16, 2026, at 4:00 P.M. This filing is a Form S-3, with the CIK 0001771910 and file number 333-294191. The filing impact and sentiment are both neutral.
ADC Therapeutics (ADCT) registers 9.83M shares issuable on HCR warrants
ADC Therapeutics (ADCT) has filed a resale prospectus to register 9,834,776 common shares, which are issuable upon the exercise of warrants previously issued to HealthCare Royalty Management, LLC (HCR) on February 18, 2026. While the company will not receive proceeds from the direct resale of these shares by the warrant holders, it could receive up to $37.5 million if the warrants are exercised for cash, with these funds designated for working capital and general corporate purposes. The warrants have an exercise price of $3.8130 per share and are exercisable until December 31, 2030, though transfer restrictions apply until December 31, 2027.
ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones
ADC Therapeutics announced that its drug ZYNLONTA has a peak U.S. revenue potential of $600 million to $1 billion. This projection is based on expanded clinical milestones, indicating strong future growth for the company's key therapeutic asset.
ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones
ADC Therapeutics announced that ZYNLONTA, its approved drug for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has a projected peak revenue potential in the U.S. of $600 million to $1 billion. The company also presented new clinical data and outlined plans for further development, including combination therapies and studies in new indications. These initiatives aim to expand ZYNLONTA's market reach and patient population.
ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1%
ADC Therapeutics SA (ADCT) reported a wider Q4 2025 adjusted loss of $0.29 per share, missing the expected -$0.27. The company generated $22.3M in revenue for the quarter. ADC Therapeutics focuses on antibody drug conjugate technology, with its lead product ZYNLONTA having received accelerated approval from the U.S.
ADC Therapeutics (NYSE:ADCT) Reaches New 12-Month High Following Strong Earnings
ADC Therapeutics (NYSE:ADCT) stock hit a new 52-week high after reporting better-than-expected Q4 earnings and product revenues, demonstrating commercial traction for its drug ZYNLONTA. Management reaffirmed ZYNLONTA's peak revenue target and highlighted upcoming clinical trial data as potential catalysts for further growth. The company remains unprofitable but has sufficient cash reserves into at least 2028, with analysts maintaining a "Moderate Buy" consensus.
[ARS] ADC Therapeutics SA SEC Filing
ADC Therapeutics (ADCT) reported strategic progress in 2025, focusing on ZYNLONTA development and commercial execution, ending the year with an estimated $261M cash balance and an expected cash runway through at least 2028. Key clinical milestones include anticipated topline LOTIS-5 PFS results in Q2 2026, completion of ~100-patient enrollment in LOTIS-7 in H1 2026, and full LOTIS-5/LOTIS-7 data by end of 2026. The company also underwent a strategic reprioritization, discontinuing solid-tumor preclinical programs, reducing its workforce by ~30%, and closing UK operations, while raising $160M through equity offerings, with ZYNLONTA projecting potential U.S. peak revenues of $600M–$1B.
ADC Therapeutics 2025 10-K: $81.4M Revenue, $(1.12) EPS
ADC Therapeutics reported total revenue of $81.4 million for 2025, a 14.9% increase year-over-year, driven by product sales and licensing, with a net loss per share of $(1.12), an improvement from the previous year. The company narrowed its net loss and operating loss, reflecting commercial traction and cost actions, and expects current resources to fund operations for at least 12 months. A restructuring in 2025 included a 30% workforce reduction and facility closure, incurring $13.1 million in charges.
According to the latest filings submitted to the U.S. Securities and Exchange Commission (SEC), some shareholders of the biopharmaceutical company ADC Therapeutics SA may gradually sell their holdings of the company's common stock over a period of tim
Recent SEC filings indicate that some shareholders of ADC Therapeutics SA plan to gradually sell up to 9,834,776 shares of the company's common stock. This secondary market offering, initiated by existing shareholders, will not provide new financing for the company. Market participants are advised to monitor these sales closely to assess their potential impact on ADC Therapeutics' stock price.
ADC Therapeutics SA (ADCT) Posts Fourth Quarter Loss, Surpasses Revenue Projections
ADC Therapeutics SA (ADCT) reported a significantly smaller-than-expected loss of $0.04 per share for the fourth quarter, beating the Zacks Consensus Estimate of $0.32. The company also exceeded revenue projections, generating $23.06 million against an estimate of $20.41 million. While ADCT shares have risen almost 20% year-to-date, their future performance will depend on management commentary and evolving earnings forecasts.
ADC Therapeutics (NYSE:ADCT) Shares Gap Up After Strong Earnings
ADC Therapeutics (NYSE:ADCT) shares gapped up after the company announced stronger-than-expected quarterly earnings, beating the consensus EPS estimate by $0.23. The stock rose approximately 8.2%, opening at $4.54 after a previous close of $4.23. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $7.33, and institutional ownership remains significant at around 41.1%.
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Expectations By $0.23 EPS
ADC Therapeutics (NYSE:ADCT) reported earnings results, topping consensus estimates by $0.23 with an EPS of ($0.09) for the quarter. Following the report, the stock rose 2.4% to open at $4.21. Institutional investors hold 41.10% of the stock, and analysts maintain a "Moderate Buy" consensus rating with an average target price of $7.33.
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) reported a smaller-than-expected loss of $0.04 per share for Q4 2025, significantly outperforming the Zacks Consensus Estimate of a $0.32 loss. The company also exceeded revenue expectations, posting $23.06 million against an estimate of $16.91 million. Despite a mixed outlook for estimate revisions, the stock currently holds a Zacks Rank #3 (Hold).
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q4 2025 Earnings
ADC Therapeutics SA -REDH ($ADCT) reported its Q4 2025 earnings, surpassing analyst estimates for both earnings per share and revenue. The company posted -$0.04 EPS against an estimated -$0.27, and revenue of $23,060,000, beating the $21,817,800 estimate. The article also details significant hedge fund activity with several institutions increasing or decreasing their stakes in ADCT during the same quarter.
ADC Therapeutics reports Q4 revenue $22.3M, FY2025 revenue $73.6M; cash $261.3M
ADC Therapeutics (ADCT) reported Q4 2025 net product revenue of $22.3 million and full-year revenue of $73.6 million, holding $261.3 million in cash by December 31, 2025. The company posted a net loss of $6.4 million for Q4 and $142.6 million for the full year 2025. Management anticipates key clinical readouts, including LOTIS-5 topline results in Q2 2026, with financial runway expected to extend at least into 2028.
ADC Therapeutics reports Q4 revenue of $22.3 million
ADC Therapeutics SA reported net product revenue of $22.3 million for Q4 2025 and $73.6 million for the full year, an increase of approximately 6% over 2024. Despite weak gross profit margins and a net loss, the company's stock has seen a 145% return over the past year. ADC Therapeutics also amended its royalty purchase agreement, reducing change of control payments and maintaining a strong cash position.
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
ADC Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2025, revealing net product revenue of $22.3 million and $73.6 million, respectively, and cash and cash equivalents of $261.3 million. The company expects topline data from its LOTIS-5 Phase 3 trial in Q2 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026, and anticipates a cash runway extending at least into 2028. An amendment to the HealthCare Royalty financing agreement was also reported, offering increased strategic flexibility.
Earnings Scheduled For March 10, 2026
This article lists companies scheduled to report quarterly earnings on March 10, 2026, both before and after the bell. It provides estimated earnings per share and revenue figures for numerous companies across various sectors, such as Ultralife, Kohl's, NIO, Oracle, and Groupon. The report helps investors anticipate upcoming financial disclosures.
ADC Therapeutics Narrows Losses, Supported By Higher Product Revenue And Ongoing Restructuring
ADC Therapeutics (ADCT) reported narrowed net losses for the fourth quarter and full-year 2025, driven by higher product revenue and ongoing restructuring efforts. The company's net loss significantly improved in Q4 2025 compared to the prior year, attributed to lower operating expenses and a favorable royalty adjustment. ADC ended 2025 with $261.3 million in cash, providing runway into 2028, and anticipates key clinical data from its LOTIS studies for ZYNLONTA in 2026.
ADC Therapeutics SA expected to post a loss of 27 cents a share - Earnings Preview
ADC Therapeutics SA (ADCT) is projected to report a loss of 27 cents per share in its upcoming earnings announcement. This information is based on an earnings preview from Reuters. Further details likely require logging in or creating an account on the platform where the article is hosted.
ADC Therapeutics (ADCT) to Release Earnings on Tuesday
ADC Therapeutics (ADCT) is scheduled to release its Q4 2025 earnings before market open on Tuesday, March 10th, with analysts forecasting ($0.32) EPS and $22.29 million in revenue. The stock, which recently traded at $4.04 with a market cap of $500.9 million, has a "Moderate Buy" consensus rating and an average price target of $7.33 from analysts. Institutional investors currently own 41.1% of the company, with several firms increasing their stakes in recent quarters.
ADC Therapeutics to Host Q4 2025 Financial Results Call
ADC Therapeutics will host a conference call on March 10, 2026, to discuss its Q4 and full-year 2025 financial results. The company's drug ZYNLONTA has received accelerated FDA and conditional European Commission approval for treating certain lymphomas. ADC Therapeutics, headquartered in Switzerland with operations in New Jersey, specializes in the development, manufacturing, and commercialization of antibody-drug conjugates (ADCs).
ADC Therapeutics delivers 70% return as Fair Value target hit
InvestingPro's Fair Value analysis correctly identified ADC Therapeutics (NYSE:ADCT) as significantly undervalued in November 2024, trading at $2.39. Sixteen months later, the stock hit its target of $4.05, delivering a 69.46% return. This success highlights the effectiveness of Fair Value analysis in identifying mispriced opportunities and guiding investment decisions.
ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Moderate Buy" from Brokerages
ADC Therapeutics SA (NYSE:ADCT) has received a consensus "Moderate Buy" rating from five analysts, with four recommending a buy and one a sell. The average 12-month price target is $7.33. The company, which specializes in antibody-drug conjugates, has seen notable institutional buys in the fourth quarter, with 41.10% of the stock owned by institutional investors.
ADCT: Pivotal data and new combinations position ZYNLONTA for major growth in lymphoma markets
ADC Therapeutics’ drug ZYNLONTA is expected to see significant growth, driven by upcoming pivotal phase III and combination study data. These studies target both complex and broadly accessible diffuse large B-cell lymphoma (DLBCL) segments, with early results indicating high response rates and manageable safety. The company anticipates revenue growth to $600 million–$1 billion through expansion into indolent lymphomas and second-line treatments.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics SA announced the grant of options to purchase 135,000 of the Company's common shares to three new employees as a material inducement for their employment. These grants were approved by the Compensation Committee of the Board of Directors under the Company's Inducement Plan and vest over four years, subject to continued employment. This move aligns with NYSE's Listed Company Manual Rule 303A.08, aiming to motivate and reward employee contributions.
ADC Therapeutics sets March 10 call on 2025 results and operations
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on March 10, 2026, at 8:30 a.m. EDT to report its fourth quarter and full-year 2025 financial results and provide operational updates. The company's stock, ADCT, was up 1.95% recently, while historically, similar earnings call announcements have led to a modest average next-day decrease of 4.5% in stock price. Investors can register in advance for the call, which will include details on financial performance for the period ended December 31, 2025, and the webcast archive will be available for 30 days.
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
ADC Therapeutics SA (NYSE: ADCT) announced it will host a conference call and live webcast on Tuesday, March 10, 2026, at 8:30 a.m. EDT. The call will report financial results for the fourth quarter and full year ended December 31, 2025, and provide operational updates. Interested parties can register for the call or access the webcast through the investors section of the company's website.
ADCT Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Adc Therapeutics Sa (ADCT), including its income statement, balance sheet, and cash flow statement, derived from SEC filings. The company's financial health indicators reveal weak profitability with a negative operating margin, modest revenue growth, but strong liquidity. Key metrics such as negative net income, free cash flow, and EPS highlight financial challenges, while specific sections address common investor questions about revenue, profitability, and debt.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics SA (NYSE: ADCT) announced on March 2, 2026, that it has granted options to purchase an aggregate of 135,000 common shares to three new employees. These grants were made as a material inducement for their employment, approved by the Compensation Committee, and are subject to a four-year vesting schedule tied to continued employment. The company issued this press release in accordance with NYSE's Listed Company Manual Rule 303A.08.
ADC Therapeutics to Participate in March Investor Conferences
ADC Therapeutics (NYSE: ADCT) announced its participation in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference and the Jefferies Biotech on the Beach Summit. CEO Ameet Mallik will present at the TD Cowen conference, and the company will hold one-on-one meetings at the Jefferies event. A webcast of the TD Cowen presentation will be available on ADC Therapeutics' investor relations website.
ADC Therapeutics (NYSE:ADCT) Shares Up 6.7% - Time to Buy?
ADC Therapeutics (NYSE:ADCT) saw its shares rise by 6.7% to $4.375 on Monday, with analysts largely assigning a "Moderate Buy" rating and an average price target of $7.50. Institutional investors, including Prosight Management and Nantahala Capital Management, have been increasing their stakes in the company. ADC Therapeutics specializes in developing antibody-drug conjugates for hematological malignancies.
ADC Therapeutics SA announced that, in the event of a change of control, the acquirer will continue to pay royalties to the healthcare royalty company until the originally agreed cap amount is reached.
ADC Therapeutics SA has announced that any acquirer in a change of control event will be obligated to continue paying royalties to the healthcare royalty company. This commitment remains in effect until the initially agreed-upon cap amount for royalties is fully met. This arrangement ensures the consistent flow of concession revenues, irrespective of shifts in the company's ownership.
ADC Therapeutics SA (ADCT) recently released its performance outlook, expecting the company to enter a substantial growth phase starting in 2027.
ADC Therapeutics SA (ADCT) anticipates entering a substantial growth phase beginning in 2027, with potential annual revenue in the US market estimated between $600 million and $1 billion. This optimistic forecast is based on the commercialization of its core product pipeline and strategic market expansion within oncology treatment. The company's future financial performance is contingent on the successful execution of clinical development and market penetration strategies.
$750M payout risk eased as ADC Therapeutics rewrites royalty deal
ADC Therapeutics (NYSE: ADCT) has amended its royalty purchase agreement with HealthCare Royalty, reducing the change-of-control payment obligation to $150 million through December 31, 2027, and $200 million thereafter, down from a previous $750 million. In exchange, HealthCare Royalty received warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81. This agreement provides ADC Therapeutics with greater strategic flexibility, particularly for its drug ZYNLONTA, which the company projects could achieve $600 million to $1 billion in annual US peak revenue.
ADC Therapeutics grants warrants to Healthcare Royalty By Investing.com
ADC Therapeutics (NYSE:ADCT) has granted warrants to Healthcare Royalty, allowing them to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share. The biopharmaceutical company anticipates significant growth starting in 2027 and projects potential peak revenue in the United States to range from $600 million to $1 billion annually. This move is part of the company's financial strategy.
Healthcare Royalty Partners granted warrants to purchase approximately 9.8 million ordinary shares to ADC Therapeutics SA.
Healthcare Royalty Partners has granted warrants to ADC Therapeutics SA, allowing them to purchase roughly 9.8 million ordinary shares. The exercise price for these warrants is set at $3.81 per share. This agreement could provide ADC Therapeutics SA with a capital injection and offers investors the right to acquire shares at a fixed future price.
ADC Therapeutics Amends HCR Royalty Financing, Sets $150–$200 Million Change-of-Control Payment
ADC Therapeutics has amended its royalty financing agreement with HealthCare Royalty Management, updating the terms for change-of-control and buyout options. The company will now owe $150 million if a change of control occurs by December 31, 2027, or $200 million thereafter, amounts not reduced by prior royalties. This amendment replaces previous obligations that could have reached up to $750 million, providing clearer and potentially lower future payment obligations for ADC Therapeutics.
